Revenue
2010
2012
2013
2014
2022
2023
2024
2025
Eloxx Pharmaceuticals, Inc. (ELOX)
Price$18.25Cached quote
Net income
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2021
2022
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 · Dec 31 | 2017 · Jun 30 | 2016 · Dec 31 | 2016 · Jun 30 | 2015 · Dec 31 | 2015 · Jun 30 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.4M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | $182,229 | $7,819 | $200,000 | — | $140,000 | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $3.1M | $3.6M | $8.6M | $23.7M | $22.9M | $14.6M | $26.3M | $20.5M | $16.4M | $733,661 | $9.0M | $2.2M | $5.8M | $4.6M | $3.3M | $2.1M | $2.6M | $3.7M | $2.6M | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $6.4M | $8.8M | $17.3M | $34.4M | $66.0M | $33.5M | $50.6M | $47.6M | $20.4M | — | $9.8M | — | $6.3M | — | — | $4.7M | $5.6M | — | $5.0M | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$6.4M | −$2.5M | −$17.3M | −$34.4M | −$66.0M | −$33.5M | −$50.6M | −$47.6M | −$20.4M | −$4.6M | −$9.8M | −$11.2M | −$6.3M | −$18.1M | −$9.1M | −$4.7M | −$5.4M | −$7.9M | −$4.8M | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | −38.81% | — | — | — | — | — | — | — | — | — | — | — | — | −5,019.95% | −59,476.92% | −2,705.76% | — | −3,461.80% | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$6.4M | −$2.4M | −$17.2M | −$34.3M | −$65.9M | −$33.4M | −$50.5M | −$47.3M | −$20.4M | −$4.5M | −$9.8M | −$11.1M | −$6.3M | −$17.9M | −$8.8M | −$4.4M | −$5.2M | −$7.8M | −$4.7M | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | — | −38.26% | — | — | — | — | — | — | — | — | — | — | — | — | −4,828.07% | −55,721.59% | −2,576.75% | — | −3,371.40% | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$6.0M | −$3.1M | −$17.1M | −$36.1M | −$66.7M | −$34.6M | −$50.9M | −$47.2M | −$21.2M | −$5.8M | −$9.8M | −$8.3M | −$6.4M | −$18.1M | −$9.2M | −$6.1M | −$5.1M | −$7.3M | −$13.4M | −$5.7M | −$4.6M | −$3.3M | −$3.3M | −$3.0M | −$3.7M | −$2.8M | −$3.0M | −$2.0M | −$3.3M | −$1.2M |
| Net profit margin | — | −49.43% | — | — | — | — | — | — | — | — | — | — | — | — | −5,062.44% | −78,303.39% | −2,533.07% | — | −9,559.65% | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$5.39 | -$9.24 | -$72.93 | -$183.15 | -$419.65 | -$378.40 | -$589.60 | -$638.00 | -$2,090.00 | -$118.80 | -$1,144.00 | -$184.80 | $734.80 | -$576.40 | -$1,113.20 | -$2,248.40 | -$3,520.00 | -$6,160.00 | -$29,480.00 | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$5.39 | -$9.24 | -$72.93 | -$183.15 | -$419.65 | -$378.40 | -$589.60 | -$638.00 | -$2,090.00 | -$118.80 | -$1,144.00 | -$184.80 | $734.80 | -$576.40 | -$1,113.20 | -$2,248.40 | -$3,520.00 | -$6,160.00 | -$29,480.00 | — | — | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
≈41.44%of listed shares
Aggarwal Sumit1.67M shares · Feb 28, 2026
View holders
| Holder | % owned |
|---|---|
Aggarwal Sumit | ≈41.44%1.67M shares |
Nantahala Capital Management, LLC | 19.82%800K shares |
EcoR1 Capital, LLC | 9.91%400K shares |
Aberdeen Group plc | 9.91%400K shares |
SAMSARA BIOCAPITAL, LLC | 9.91%400K shares |
Siren, L.L.C. | 9.91%400K shares |
Stonepine Capital Management, LLC | 9.84%397.16K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 1.95%78.68K shares |
Androski Lindsay | ≈0.39%15.75K shares |
Walts Alan Edmund | ≈0.39%15.57K shares |
Rubin Steven D | ≈0.36%14.63K shares |
VANGUARD FIDUCIARY TRUST CO | 0.26%10.6K shares |
SEVEN GRAND MANAGERS, LLC | 0.25%10K shares |
MORGAN STANLEY | 0.04%1.54K shares |
Vanguard Global Advisers, LLC | 0.02%718 shares |
UBS Group AG | 0.02%637 shares |
WELLS FARGO & COMPANY/MN | <0.01%126 shares |
ROYAL BANK OF CANADA | <0.01%98 shares |
Pioneer Family Office, LLC | <0.01%96 shares |
Altshuler Shaham Ltd | <0.01%25 shares |
Percentages use 4.04M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...
